Related Experiment Video
Updated: Dec 31, 2025
Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
A novel retinoblastoma therapy from genomic and epigenetic analyses
Jinghui Zhang1, Claudia A Benavente, Justina McEvoy
1Department of Computational Biology and Bioinformatics, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Abstract:
Retinoblastoma is an aggressive childhood cancer of the developing retina that is initiated by the biallelic loss of RB1. Tumours progress very quickly following RB1 inactivation but the underlying mechanism is not known. Here we show that the retinoblastoma genome is stable, but that multiple cancer pathways can be epigenetically deregulated. To identify the mutations that cooperate with RB1 loss, we performed whole-genome sequencing of retinoblastomas. The overall mutational rate was very low; RB1 was the only known cancer gene mutated. We then evaluated the role of RB1 in genome stability and considered non-genetic mechanisms of cancer pathway deregulation. For example, the proto-oncogene SYK is upregulated in retinoblastoma and is required for tumour cell survival. Targeting SYK with a small-molecule inhibitor induced retinoblastoma tumour cell death in vitro and in vivo. Thus, retinoblastomas may develop quickly as a result of the epigenetic deregulation of key cancer pathways as a direct or indirect result of RB1 loss.
Insights
Retinoblastoma, a rapid childhood retinal cancer, arises from RB1 gene loss. Tumors show stable genomes but epigenetic changes in cancer pathways, like SYK upregulation, drive rapid progression.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Retinoblastoma is an aggressive childhood retinal cancer initiated by biallelic loss of the RB1 gene.
- Rapid tumor progression following RB1 inactivation suggests underlying mechanisms beyond genetic mutations.
Purpose of the Study:
- To investigate the mechanisms driving rapid retinoblastoma progression after RB1 loss.
- To identify cooperating genetic or epigenetic events in retinoblastoma development.
Main Methods:
- Whole-genome sequencing of retinoblastoma tumors.
- Evaluation of RB1's role in genome stability.
- Assessment of epigenetic deregulation in cancer pathways.
- In vitro and in vivo testing of SYK inhibition.
Main Results:
- Retinoblastoma genomes are genetically stable with low mutation rates.
- RB1 was the only consistently mutated known cancer gene.
- Epigenetic deregulation of cancer pathways, including SYK upregulation, was observed.
- Targeting SYK with inhibitors induced retinoblastoma cell death.
Conclusions:
- Retinoblastoma progression is driven by epigenetic deregulation of cancer pathways, not solely genetic mutations.
- RB1 loss may lead to epigenetic changes that promote rapid tumor growth.
- SYK is a potential therapeutic target for retinoblastoma.
More Related Videos
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...